JP2023533485A5 - - Google Patents

Info

Publication number
JP2023533485A5
JP2023533485A5 JP2022580425A JP2022580425A JP2023533485A5 JP 2023533485 A5 JP2023533485 A5 JP 2023533485A5 JP 2022580425 A JP2022580425 A JP 2022580425A JP 2022580425 A JP2022580425 A JP 2022580425A JP 2023533485 A5 JP2023533485 A5 JP 2023533485A5
Authority
JP
Japan
Prior art keywords
chelating agent
copper chelating
composition according
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533485A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047297 external-priority patent/WO2021263250A2/en
Publication of JP2023533485A publication Critical patent/JP2023533485A/ja
Publication of JP2023533485A5 publication Critical patent/JP2023533485A5/ja
Pending legal-status Critical Current

Links

JP2022580425A 2019-06-26 2021-08-24 重症型の肺高血圧症の治療方法 Pending JP2023533485A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962866781P 2019-06-26 2019-06-26
PCT/US2021/047297 WO2021263250A2 (en) 2019-06-26 2021-08-24 Method of treating severe forms of pulmonary hypertension

Publications (2)

Publication Number Publication Date
JP2023533485A JP2023533485A (ja) 2023-08-03
JP2023533485A5 true JP2023533485A5 (https=) 2024-09-02

Family

ID=73891720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580425A Pending JP2023533485A (ja) 2019-06-26 2021-08-24 重症型の肺高血圧症の治療方法

Country Status (4)

Country Link
US (1) US12268710B2 (https=)
JP (1) JP2023533485A (https=)
CN (1) CN112138024A (https=)
WO (1) WO2021263250A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138024A (zh) * 2019-06-26 2020-12-29 里弗斯Pah有限责任公司 治疗严重形式的肺动脉高压的方法
GB2612210B (en) * 2020-06-24 2025-08-27 Reverspah Llc Pharmaceutical composition comprising a tetrathiomolybdate salt and a diethylcarbamazine
CN118524835A (zh) * 2021-11-10 2024-08-20 瑞沃斯帕有限责任公司 用于治疗癌症的方法和组合物
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer
JP2025523707A (ja) * 2022-05-28 2025-07-23 アヴァリン ファーマ インク． ニンテダニブおよびニンテダニブの組み合わせ乾燥粉末組成物と使用
CN115737661A (zh) * 2022-10-24 2023-03-07 中国人民解放军海军军医大学第一附属医院 一种黄芩苷在制备抑制视网膜新生血管的药物中的应用
CN115624562B (zh) * 2022-12-02 2023-05-09 首都医科大学附属北京友谊医院 黄芩苷在制备治疗对免疫检查点抑制剂无应答/超进展的肿瘤的药物中的应用
CN118078999B (zh) * 2024-02-23 2025-03-18 中山大学附属第一医院 铜离子螯合剂联合NF-κB抑制剂在制备肿瘤治疗药物中的应用
CN120789268B (zh) * 2025-09-16 2025-12-05 中南大学 Aldh1a2抑制剂和检测aldh1a2或ra的试剂的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649577A (zh) 2002-03-08 2005-08-03 普罗特米克斯公司 预防和/或治疗心血管疾病和/或相关的心衰
CA2675230A1 (en) * 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
US10195164B2 (en) * 2015-05-13 2019-02-05 Duke University Use of disulfiram for inflammatory breast cancer therapy
WO2017019892A1 (en) * 2015-07-28 2017-02-02 Insmed Incorporated Compositions comprising copper chelators and methods of use thereof for treating vasculopathies
CN106257609B (zh) 2016-08-22 2018-03-06 河南师范大学 一种制备单层1t相二硫化钼/石墨烯复合材料的方法
CN112138024A (zh) 2019-06-26 2020-12-29 里弗斯Pah有限责任公司 治疗严重形式的肺动脉高压的方法
WO2022035813A1 (en) * 2020-08-10 2022-02-17 Reverspah Llc Method and composition for treating corona virus, influenza, and acute respiratory distress syndrome
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer

Similar Documents

Publication Publication Date Title
JP2023533485A5 (https=)
JP2019536805A5 (https=)
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
EA020193B1 (ru) Комбинации, включающие метотрексат и ингибиторы дигидрооротатдегидрогеназы (dhodh)
JP2006504795A5 (https=)
JP6571538B2 (ja) 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用
JPWO2004019928A1 (ja) 肝疾患治療剤
TWI794288B (zh) 科帕利普(copanlisib)調配物
JP2019501226A5 (https=)
JP2005501825A5 (https=)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
RU2004131214A (ru) Способы лечения когнитивных расстройств
RU2019134940A (ru) Лечение гепатоцеллюлярной карциномы
RU2346686C2 (ru) Комбинации, включающие эпотилоны и антиметаболиты
ME01335B (me) Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura
JP2007534634A5 (https=)
US20070197607A1 (en) Continuous Dosing Regimen
JP2018525447A5 (https=)
JP2023011549A5 (https=)
JP2023509191A (ja) 癌を治療するための組み合わせ療法
JP3837769B2 (ja) 抗ウイルス剤
EP3493849B1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
JP2006514063A5 (https=)
CN1330308C (zh) 含有4－吡啶基甲基酞嗪的联合产品及其应用
JP2004533434A (ja) テガフール、ウラシル、フォリン酸およびシクロホスファミドの投与による腫瘍の治療方法